Method for chemoprevention of prostate cancer
AssigneeThe University of Tennessee Research Corporation
InventorsMitchell S. Steiner, Sharan Raghow
Life of this patent
Estimating the term…
Abstract
This invention relates to the chemoprevention of prostate cancer and, more particularly, to a method of suppressing or inhibiting latent prostate cancer comprising administering to a mammalian subject a chemopreventive agent and analogs and metabolites thereof. The chemopreventive agent prevents, prevents recurrence of, suppresses or inhibit prostate carcinogenesis; and treats prostate cancer.
Claims34
A method of suppressing or inhibiting latent prostate cancer of a subject comprising:
- administering to the subject, a pharmaceutical preparation comprising a selective estrogen receptor modulator (SERM);
- and a pharmaceutically acceptable salts, esters, or N-oxides, or mixtures thereof, thereby suppressing or inhibiting latent prostate cancer of the subject.
A method of treating a subject with prostate cancer comprising:
- administering to the subject, a pharmaceutical preparation comprising a selective estrogen receptor modulator (SERM);
- and a pharmaceutically acceptable salts, esters, or N-oxides, or mixtures thereof, thereby treating the subject with prostate cancer.
A method of suppressing or inhibiting pre-malignant lesions of prostate cancer of a subject comprising:
- administering to the subject a pharmaceutical composition comprising an selective estrogen receptor modulator (SERM);
- and a pharmaceutically acceptable salts, esters, or N-oxides, or mixtures thereof, thereby suppressing or inhibiting the pre-malignant lesions of prostate cancer of the subject.
A method of treating a subject with pre-malignant lesions of prostate cancer comprising the steps of:
- administering to the subject, a pharmaceutical composition comprising an selective estrogen receptor modulator (SERM);
- and pharmaceutically acceptable salts, esters, or N-oxides, or mixtures thereof, thereby treating the subject with pre-malignant lesions of prostate cancer.
Dependencies are inferred from the claim text.